Is It Too Early To Buy Insmed Stock?
Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?
Insmed (INSM) shares are down 28.4% over the past 12 months, yet they jumped 53.6% in the past month alone. Even after that bounce, the stock closed 31.7% below its December 2025 high on November 19, 2026. The company still loses money, so what exactly would you be paying for at today’s price? Mostly you would be paying for sales growth, and the next tests are an FDA target date of January 28, 2027 and a report in February.
Insmed shares jumped 53.6% in a month, yet they are still down 28.4% over 12 months. Swings like that are hard to sit through when a single drug maker holds a big part of your savings. Instead of one company, the Trefis High Quality (HQ) Portfolio owns 30 quality companies in equal amounts, and it is up more than 105% since September 2020. Look inside HQ.

How Much Are You Paying For Insmed’s Sales?
At today’s price, you would be paying 20.8 times Insmed’s sales over the past 12 months, against 3.1 times for the S&P 500. A price-to-earnings ratio means nothing here because Insmed has no profit to divide by. So you are buying the sales, which have grown fast. Revenue reached $1.52 billion in the 12 months to September 2026, up 240.0% from a year earlier.
Most of Insmed’s sales now come from one drug, BRINSUPRI. Management calls it the first-ever approved foundational medicine in bronchiectasis, a long-term lung disease. It brought in $400.1 million of Insmed’s $524 million in revenue in the third quarter of 2026.
As those sales grew, the company’s loss narrowed. Insmed’s operating loss over the past 12 months was 41.7% of revenue, against 221.5% a year earlier. That is its narrowest loss as a share of revenue at any of the 32 quarter ends since the end of 2018.
What Sales Is Insmed Expected To Deliver Next?
Analysts expect revenue of about $606 million for the fourth quarter of 2026, putting it above the third quarter’s total. Management has raised its own bar as well. On October 29, the company lifted its full-year 2026 BRINSUPRI revenue forecast to $1.375 billion at the midpoint, from $1.325 billion.
The price appears to assume growth well beyond 2026. Management forecasts that its three lead respiratory medicines will together grow sales more than 20% a year over the next 10-plus years. It also expects to turn cash flow positive in 2027. Insmed’s reported free cash outflow has shrunk in each quarter of 2026, to $42.1 million in the third quarter from $264 million in the fourth quarter of 2025.
Those forecasts depend on more patients starting BRINSUPRI. Insmed treated tens of thousands of patients in the drug’s first year, while hundreds of thousands of diagnosed patients are still waiting, management said. BRINSUPRI may also face a rival. Management said it expects another company’s drug of the same type, a DPP1 drug, to be approved.
Insmed’s Next Report, And How Its Stock Has Reacted
Insmed is expected to report its fourth-quarter 2026 results in February 2027. Before that, the FDA has a January 28, 2027 target date to rule on a wider label for ARIKAYCE, Insmed’s other main drug, in MAC lung disease, a type of lung infection. Management said wider labels in the U.S. and Japan could widen ARIKAYCE’s reach in each region. It could go from about 15,000 patients today to more than 100,000.
Across its last six reports, Insmed stock’s moves over the two trading days after each one ranged from a 4.1% fall to a 3.3% gain. The report days themselves brought far bigger swings in both directions. The stock fell 23.4% on May 7, 2026, a report day. It rose 33.9% on August 6, 2026, the day of the next report. The latest report, on October 29, 2026, brought a 15.1% rise.
The stock has also fallen hard in past market shocks, dropping 40.0% in the 2022 inflation shock against 24.0% for the S&P 500. With swings like these, a buyer who waits could get a lower price, or miss a higher one.
Insmed’s February report will show how its fourth-quarter sales compare with what analysts expect, and whether the cash outflow kept shrinking.
Until then, Insmed’s price can swing hard in either direction. Money you set aside for Insmed can still earn something while you wait for the February report.
Waiting To Buy Insmed? Why Let Your Cash Sit Idle?
The right price can take months. Meanwhile, the Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, from 50 stocks with at least 10 straight years of dividends. Why not choose a better approach?
Spot an error or want more like this? Tell us in 10 seconds.